Stanford Cancer Institute
Translating Stanford discoveries into individualized cancer care
Transforming Cancer Care
Stanford Cancer Initiative is an ambitious program to transform the care experience of every cancer patient treated at Stanford. The Initiative combines the latest research and information management protocols with multi-disciplinary, patient-centered care to improve quality of life and overall health outcomes. Integrating leading-edge research and comprehensive care to dramatically change the prognosis and treatment of cancer.
National Cancer Institute Designation
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
Stanford scientists were able to engineer immune cells known as macrophages to detect and flag cancer in mice. The researchers hope the technique can be used for early cancer diagnostics in humans.
Stanford researchers have found a way to predict who will suffer heart problems from a common breast-cancer drug, as well as identified an FDA-approved medication that could mitigate those side effects.
Some breast cancers return decades later. Now, a researcher at Stanford, joined by collaborators at several other institutions, has subcategorized tumors to predict recurrence, guide treatment decisions and improve drug development.
Cancer Clinical Trials
Stanford Cancer Institute offers leading edge research and compassionate care with over 250 actively recruiting clinical trials, investigating a broad spectrum of new diagnostic, prevention and treatment strategies.